Palmitoylation of death receptor p75<sup>NTR</sup> contributes to Alzheimer's disease progression by regulating APP trafficking and degradation.

A recent randomized, placebo-controlled phase 2a clinical trial using a small molecule “modulator “ of p75 NTR found mild improvements in several AD biomarkers as well as cognitive functions, although the latter did not reach statistical significance [ 21 ], supporting the use of p75 NTR as a therapeutic target in AD.

also in 111,027 other papers